

## IN THIS ISSUE!

- **Upcoming Webinar: New and Notable Clinical and MirixaPro<sup>SM</sup> Platform Updates**
- **MirixaPro<sup>SM</sup> New & Notable Clinical Updates**
  - American Diabetes Association's Standards of Care
  - GOLD guidelines for COPD
- **MirixaPro<sup>SM</sup> Quality Tips**
  - Documenting a Medication Action Plan (MAP)
  - Prescriber Outreach: Critical to Driving Positive Outcomes
- **Compliance Tip: Attesting To and Authorizing a Case**
- **Tips to Improve Performance with Mirixa Programs**

### UPCOMING WEBINAR:

## New and Notable Clinical and MirixaPro Platform Updates



Join us for a review of recent changes to clinical guidelines and the MirixaPro platform.

**Wednesday, June 7 from 2:00 PM-2:30 PM EST**

The clinical updates review will focus on Standards of Care from the American Diabetes Association and GOLD 2017 guidelines for COPD. This webinar will also include a quick demo documenting a Comprehensive Medication Review (CMR) case.

Register for this webinar by logging on to MirixaPro, navigating to the Training & Support section of the home page, clicking on 'Live Training Sessions Schedule,' and searching 'New and Notable: June 2017'. [Click here to begin registration.](#)

## New & Notable Clinical Updates

The American Diabetes Association's (ADA) Standards of Care and GOLD guidelines for COPD were recently updated. Notable changes include:

- To align with existing data for hypertension, the ADA recommends that, for patients without albuminuria, any of the four classes of blood pressure medications with demonstrated beneficial cardiovascular outcomes may be used (ACE inhibitors, ARBs, thiazide-like diuretics, or dihydropyridine calcium channel blockers).
- Based on the results of two large clinical trials, the ADA added a recommendation to consider empagliflozin (Jardiance®) or liraglutide (Victoza®) to reduce the risk of mortality in patients with established cardiovascular disease.
- GOLD guidelines for COPD now include suggestions on drug therapy algorithms (initial therapy, escalation, and de-escalation) for each patient group, instead of recommendations on initial therapy only.

These changes and more are reflected in the newly updated Clinical Reference Guides in the [Clinical Reference and Resource](#) section of the MirixaPro platform.

## MirixaPro<sup>SM</sup> Quality Tips

The MirixaPro platform works hard for you. This month we detail two helpful tips to ensure that you get the most out of the system while improving your patients' results as well: Quality Tips on the Medication Action Plan (MAP) and Prescriber Outreach.

[Click here](#) for these important quality tips.

## COMPLIANCE TIP: Attesting To and Authorizing a Case

Closing a case? You should review the attestations that you are required to make throughout the MirixaPro Platform while performing the CMR. Remember, you are attesting to the following:

- Cognitive Impairment/Recipient of Service
- Allergies
- Conditions
- Medications
- Red Flags - Safety Alerts
- Green Flags - Plan Suggested Interchange Alerts
- Blue Flags - Care Gap Alerts
- Worksheet
- Care Coordination



For complete details about Attesting to and Authorizing a Case, [read more here](#).

**Remember: By attesting to completing all required tasks, you are authorizing Mirixa and the Medicare MTM program sponsor to pay your pharmacy for the service performed. All attestations must be accurate. If an attestation is not accurate, this could be considered fraudulent billing.**

### Tips to Improve Performance with Mirixa Programs

While many users are very familiar with the way Mirixa programs work, we thought it would be helpful to provide tips to help improve the success of your Mirixa programs.

Check out the top performance tips [HERE!](#)

**Mirixa  
Support:**

**866.218.6649 [Monday - Friday 8:30am-5:30pm ET] or  
Go to 'Contact Support' on the MirixaPro platform.**



[Website](#)

[Payers](#)

[Pharmacies](#)

[About Mirixa](#)

[Careers](#)

**Mirixa**  
The Power of Pharmacy®

### Corporate Headquarters

11600 Sunrise Valley Drive, Suite 100  
Reston, VA 20191  
Phone: (703) 683-1955  
Fax: (703) 549-9165